NexgenRx Inc.
NEGXF
$0.20
$0.00351.78%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.40M | 10.87M | 10.45M | 9.85M | 9.76M |
| Total Other Revenue | 447.60K | 450.50K | 437.20K | 414.20K | 363.10K |
| Total Revenue | 11.85M | 11.32M | 10.89M | 10.26M | 10.12M |
| Cost of Revenue | 2.65M | 2.48M | 2.37M | 2.24M | 2.15M |
| Gross Profit | 9.19M | 8.85M | 8.51M | 8.02M | 7.97M |
| SG&A Expenses | 7.90M | 7.75M | 7.46M | 7.15M | 7.01M |
| Depreciation & Amortization | 933.30K | 946.30K | 961.30K | 969.10K | 983.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.49M | 11.18M | 10.79M | 10.37M | 10.14M |
| Operating Income | 355.20K | 148.00K | 92.50K | -105.90K | -15.70K |
| Income Before Tax | 208.40K | 2.30K | -27.70K | -225.40K | -113.00K |
| Income Tax Expenses | 18.60K | 19.50K | 19.20K | 19.30K | 116.30K |
| Earnings from Continuing Operations | 0.19 | -0.02 | -0.05 | -0.24 | -0.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 189.70K | -17.20K | -46.90K | -244.70K | -229.30K |
| EBIT | 355.20K | 148.00K | 92.50K | -105.90K | -15.70K |
| EBITDA | 1.26M | 1.07M | 1.03M | 851.70K | 848.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 283.46M | 282.91M | 282.32M | 281.73M | 281.54M |
| Average Diluted Shares Outstanding | 296.46M | 295.61M | 294.72M | 297.57M | 297.37M |
| Dividend Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Payout Ratio | 337.22% | -3,721.51% | -1,423.67% | -272.82% | -167.55% |
